<DOC>
	<DOCNO>NCT00556413</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together combination chemotherapy work first-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Combination Chemotherapy First-Line Therapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate patient metastatic colorectal cancer treat cetuximab FOLFIRINOX chemotherapy comprise oxaliplatin , irinotecan hydrochloride , leucovorin calcium , fluorouracil first-line therapy . Secondary - Determine objective response rate patient treat regimen . - Assess tolerability regimen patient . - Determine time response time progression patient treat regimen . - Determine survival patient treat regimen . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour day 1 8 . Patients also receive FOLFIRINOX chemotherapy comprise oxaliplatin IV 2 hour , irinotecan hydrochloride IV 30-90 minute , leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 15 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Metastatic , unresectable disease May may express EGFR gene Measurable disease , define ≥ 1 measurable lesion MRI CT scan Lesion must outside irradiated area PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Transaminases ≤ 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Creatinine ≤ 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception No peripheral symptomatic neuropathy ≥ grade 2 ( NCICTCAE ) No complete partial intestinal blockage No intestinal inflammatory disease ( e.g. , Crohn 's disease ulcerative colitis ) No chronic diarrhea No severe unstable cardiac disease ( despite treatment ) No myocardial infarction within past 6 month No neurological psychiatric illness , include epilepsy dementia No uncontrolled active infection No prior concurrent malignancy within past 5 year except curatively treat basal cell skin cancer No psychological , familial , social , geographic reason would preclude study followup PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic disease Prior fluorouracilbased adjuvant chemotherapy allow provide administer ≥ 4 week ago At least 4 week since prior concurrent experimental therapy No prior irinotecan hydrochloride , oxaliplatin , monoclonal antibody No prior intestinal resection ( e.g. , hemicolectomy extend resection small intestine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>